Podcasts about tpc

  • 286PODCASTS
  • 890EPISODES
  • 59mAVG DURATION
  • 1WEEKLY EPISODE
  • Nov 4, 2022LATEST

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about tpc

Latest podcast episodes about tpc

THE PRIMROSE CHRONICLES
SHOTS, SHELTERS & THE RED SCARE - Part 1

THE PRIMROSE CHRONICLES

Play Episode Listen Later Nov 4, 2022 25:09


This installment of THE PRIMROSE CHRONICLES is the first of two episodes in the series dealing with three societal fears that threatened the emotional well being of an entire nation because of the uncertain future  each potentially afforded American families. As somber as that sounds, the subjects are still viewed thru the limited understanding of the young narrator and host of the Chronicles. It does not wax philosophical or opinionated. That for other podcasts. TPC merely recalls the observations of one youth watching life change and unfold before him. It's a valuable effort, offering a backdrop for others to recollect their own reactions. Hopefully it will be an entertaining one as well. Enjoy

the talking greenkeeper
Adrienne Young

the talking greenkeeper

Play Episode Listen Later Oct 25, 2022 68:21 Very Popular


Adrienne Young, Hurricane Katrina survivor, mother of 3 beautiful daughters, and Assistant Golf Course Superintendent at the TPC of San Antonio joins me to break down life as a greenkeeper, and life in general.   Thanks to our sponsors: https://www.rightlineusa.com https://www.greenkeeperapp.com/marketing/ Email questions & inquires: thetalkinggreenkeeper@gmail.com

THE PRIMROSE CHRONICLES
MY OWN SCUT FARKISS AFFAIR

THE PRIMROSE CHRONICLES

Play Episode Listen Later Oct 14, 2022 23:55


The Christmas Classic, A Christmas Story, actually offers several sub-plots that are reminiscent of the incidents in the  childhood of many. Such is the case for Ralphie's yellow-eyed nemesis and a singular event in this episode of TPC. SPOILER ALERT - Ralphie comes across in his story better than the narrator does in his, but it should prove to be an enjoyable tale, nonetheless. It's little shorter in length than recent installments and ends with an important announcement about the future of Chronicles. Enjoy & blessings!

numberFire Daily Fantasy Podcasts
The Heat Check: PGA Shriners Children's Open 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Oct 4, 2022 24:54


TPC Summerlin awaits a pretty strong fall field for the PGA Tour, a field headlined by Patrick Cantlay, Max Homa, and a heavy majority of the International Presidents Cup team's roster. Which types of golfers tend to excel at TPC Summerlin? Who is in form? And whose FanDuel salary is too low? numberFire's Brandon Gdula breaks that down and talks about roster construction for this week.

The Dissident Mama Podcast
Dissident Mama, episode 64 – Keith Alexander

The Dissident Mama Podcast

Play Episode Listen Later Oct 4, 2022 76:14


Keith Alexander is co-host of The Political Cesspool, a Tennessee-based syndicated talk-radio show that has been on air now for nearly two decades. An official co-host since 2009, Alexander has an “encyclopedic knowledge and masterful intellect,” making him “both a fan favorite and indispensable member” of TPC's on-air talent. Alexander, a semi-retired lawyer who has twice run for local public office in his hometown of Memphis, is not one to shy away from provocative topics. So we talk about the triumph of liberalism and how its destructive intent came to be through coercive “civil rights,” cultural pessimism, and lawfarism, as well as the need for those on the right to not shy away from the institutions. Alexander also discusses the Eliza Fletcher murder by Cleoth Abston and Ezekiel Kelly's killing spree, both of which took place in Memphis and are summarily ignored by the subversive corporate media since the perps are black and the victims overwhelmingly white. You might wanna check out my essay on the therapeutic state and dig a little deeper on the Highlander Folk School – both of which Alexander references in our chat. Turns out, many “justice” movements that we're told are organic, grassroots uprisings to oppression are themselves just commie plots. Go figure. Be sure to visit Dissident Mama to check out all my other content. And please do consider supporting​ me through PayPal or Patreon, or by donating through Bitcoin or personal check. Thanks for listening!

THE PRIMROSE CHRONICLES
The Origins of My Worms

THE PRIMROSE CHRONICLES

Play Episode Listen Later Sep 22, 2022 32:05


It's a rather cryptic title  to introduce a very impacting element of mid 20th century youth culture.  Listeners  will have to discover for themselves the connection between title and telling as Episode 19 of TPC examines the changing landscape of music, radio and personalities in Indianapolis. 1955-1965. Seen through the eyes, ears and experiences of The Primrose Chronicles storyteller, the  battle for the ears and hearts of the teen scene between the two radio giants, WIBC & WIFE is excessively lived out before the TPC audience. It's not just about Hoosier radio. The same was played out in music markets across the nation. It's a snapshot of history, 60 years removed, + or -Settle in & enjoy,Enjoy!!

Special Conditions - A Pokémon TCG Podcast

Special Conditions Podcast 119 Recording Date - 9/8/2022 Publish Date - 9/12/2022   Giratina VSTAR is coming in with some exciting gameplay and a potential shake up to the current meta. It looks like there are a few more tricks up this rotation's sleeve, as this card takes full advantage of the Lost Zone. Could we see this card at the top of some leaderboards before the next rotation?   Arcanine is our Art of the week and we take a look at the good doggo over the years. Our examples range in style and era as we see a few different looks on Arcanine. Huge shout out to Justin for the recommendation this week!   The next Team Challenge is coming up and we still don't have TCG Live. Looks like good'ol TCGO is still doing its thing in competition. Keep a look out for 3 new Charizard Promos as TPC just keeps the Zard train rolling.    Finally we cover a few misc bits of news like some preorder bonuses, distributions and giveaways!   Card of the Week: Giratina VSTAR - https://bit.ly/SC119GiratinaVSTAR  Art of the Week: Arcanine - https://bit.ly/SC119Arcanine  Local Events - https://bit.ly/SC119Local  Team Challenge - https://bit.ly/SC119Team Charizard Promos - https://bit.ly/SC119Charizard Misc Pikachu Preorder Bonus - https://bit.ly/SC119Pikachu  Hisuian Zoroark Giveaway - https://bit.ly/SC119Zoroark    TCG Player Support the show by shopping at TCGPlayer.com using this link - https://bit.ly/TCGPlayerAffiliate    Pokémon Professor Network Merch Store - https://bit.ly/PPNMerchStore    SpecialConditions@PokemonProfessor.com  Voicemail, Text, and Picture Line - 732-835-8639   https://linktr.ee/PokemonProfessorNetwork    Music provided by GameChops and licensed through Creative Commons   ▾ FOLLOW GAMECHOPS ▾ http://instagram.com/GameChops http://twitter.com/GameChops http://soundcloud.com/GameChops http://facebook.com/GameChops http://youtube.com/GameChops http://www.gamechops.com   Intro Music Trapped In A Pokéball Dj CUTMAN and Belthesar GameChops - Ultraball http://gamechops.com/ultraball/  http://soundcloud.com/DjCUTMAN http://soundcloud.com/belthesar   Break Music He Walk - Furret / Accumula Town Remix  Dj Cutman http://soundcloud.com/djcutman  http://twitter.com/videogamedj  http://youtube.com/djcutman   TN Comics Break Music Battle with Gladion (Electro House Remix) VGR GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/videogameremixes    Outro Music Kanto Trainer Battle Mykah GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/mykah   Hosts Adam Tuttle Ken Pescatore   Producer Ken Pescatore   Executive Producer Tish Smith   Pokémon And All Respective Names are Trademark and © of Nintendo 1996-2021Pokémon Professor and Special Conditions are not affiliated with Niantic Inc., The Pokémon Company, Game Freak or Nintendo   #pokemon #pokemontcg #podcast

THE PRIMROSE CHRONICLES
Bonus Episode - From Unleashed to Gainfully Employed

THE PRIMROSE CHRONICLES

Play Episode Listen Later Sep 6, 2022 26:11


This is a unadvertised bonus bonus episode made available initially to members of the Fans of Primrose Chronicles Facebook page. It tells of the narrator and host's years attending the Indiana State Fair in the early 60's from the events described in Episode 16 during his Family Years until Episode 17 recounting the singular night The Beatles Were at the Fair. It's a thank you  to those fans who have encouraged and supported since TPC launched back in March. If you've come upon it by accident, enjoy & check out the rest of the series. Blessings!

Special Conditions - A Pokémon TCG Podcast

Special Conditions Podcast 118  Recording Date - 8/30/2022 Publish Date - 9/2/2022   Adam just couldn't contain his excitement for the TCG Advent Calendar featuring Delibird that it had to be the first thing we talked about on this episode. If you pick one up and want to trade your Delibird, it is safe to say that Adam wants it!   Our card of the week is Origin Forme Dialga, which while only seeing moderate success in the big tournaments, still makes a fun and exciting deck to try out. With super fast energy acceleration and the ability to set up quickly, it has the chance to make a big impact as early as turn two.   Phanpy takes our Art of the Week and our examples are sure to bring a smile to your face. From an aesthetic that looks like crayons to Ken's favorite crochet, Phanpy brings the joy.    Lost Origin will be here this week so we take a look at some of the highlights to look out for and how they could become players in the current meta. TPC couldn't chill out for a bit and just had to announce another expansion already, even though our next set isn't even here yet.    Worlds was a blast to watch and the Arceus-Flying Pikachu deck dominated the field. With some of the highest production value of any tournament stream to date, this Worlds was a lot of fun to spectate.    Finally we talk about the McDonald's cards that are back in Happy Meals and how you can no longer buy them a la carte. We hope you're ready to eat some cheeseburgers and McNuggets!   Advent Calander https://www.pokemon.com/us/pokemon-tcg/product-gallery/holiday-calendar/ Card of the Week: Origin Forme Dialga VSTAR - https://bit.ly/SC118Dialga Origin Forme Dialga VSTAR Turbo - https://bit.ly/SC118DialgaTurboDeck  Phanpy Art of the Week - https://bit.ly/SC118Phanpy  Lost Origin - https://bit.ly/SC118LostOrigin  Worlds Recap - https://bit.ly/SC118Worlds  McDonalds Match Battle - https://bit.ly/SC118McDonalds  McDonalds Card List - https://bit.ly/SC118McDonaldsList TCG Player Support the show by shopping at TCGPlayer.com using this link - https://bit.ly/TCGPlayerAffiliate    Pokémon Professor Network Merch Store - https://bit.ly/PPNMerchStore    SpecialConditions@PokemonProfessor.com  Voicemail, Text, and Picture Line - 732-835-8639   https://linktr.ee/PokemonProfessorNetwork    Music provided by GameChops and licensed through Creative Commons   ▾ FOLLOW GAMECHOPS ▾ http://instagram.com/GameChops http://twitter.com/GameChops http://soundcloud.com/GameChops http://facebook.com/GameChops http://youtube.com/GameChops http://www.gamechops.com   Intro Music Trapped In A Pokéball Dj CUTMAN and Belthesar GameChops - Ultraball http://gamechops.com/ultraball/  http://soundcloud.com/DjCUTMAN http://soundcloud.com/belthesar   Break Music He Walk - Furret / Accumula Town Remix  Dj Cutman http://soundcloud.com/djcutman  http://twitter.com/videogamedj  http://youtube.com/djcutman   TN Comics Break Music Battle with Gladion (Electro House Remix) VGR GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/videogameremixes    Outro Music Kanto Trainer Battle Mykah GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/mykah   Hosts Adam Tuttle Ken Pescatore   Producer Ken Pescatore   Executive Producer Tish Smith   Pokémon And All Respective Names are Trademark and © of Nintendo 1996-2021Pokémon Professor and Special Conditions are not affiliated with Niantic Inc., The Pokémon Company, Game Freak or Nintendo   #pokemon #pokemontcg #podcast

THE PRIMROSE CHRONICLES
THE INDIANA STATE FAIR - The Family Years

THE PRIMROSE CHRONICLES

Play Episode Listen Later Sep 2, 2022 22:08


Episode 16 is the first of two installments that centers on the Indiana State Fair seen thru the eyes of an elementary age boy, mid 20th century, attending the annual event in the awkward time of having to accompany his family but desiring to experience ALL it's sights and sounds on his own with his buddies. Whatever your state heritage, this chapter of TPC will resonate with any and all. Enjoy & Blessings

GCSAA Podcast
43. A conversation with TPC Deere Run's Alex Stuedemann, CGCS

GCSAA Podcast

Play Episode Listen Later Aug 25, 2022 34:22


Recorded live from TPC Deere Run during the week of the PGA Tour's John Deere Classic, this episode features Alex Stuedemann, CGCS, the longtime director of golf course operations at the Quad City standout, who is transitioning into a new position as the director of agronomy for the PGA Tour's TPC network of courses. We talk about his time in the Quad Cities, what his new role will entail and introduce you to his replacement at TPC Deere Run, Jonathan Graham.Read more about Stuedemann, Graham and the transition taking place at TPC Deere Run in this story on GCMOnline.com.The GCSAA Podcast is presented in partnership with Bayer. 

Designer's Oasis
EP 13 | Part 2 of 2 part series How to Increase Project Profitability with Time Tracking Part II - How to Audit your Project's Time & Increase Your Profitability

Designer's Oasis

Play Episode Listen Later Aug 25, 2022 31:02


It is not a crime to make money! You can delight your clients, do great work, grow a team, AND make  a good living.   Have you ever dramatically underestimated how long a project would take?    Maybe you were so far over on hours you couldn't bring yourself to invoice the client every hour of work you completed,    Perhaps you were so far in the hole that you just stopped tracking your time b/c you couldn't bear to know exactly how far off you were.    If so, this is the perfect episode for you! This is a 2 part series called “How to Increase Project Profitability with Time Tracking”   In this episode we answer questions like… How do you correctly audit your time when you look back on projects? How do you make sure you are seeing  40 - 60% profitability in your projects? What do you do if your projects are NOT profitable yet? Here's a glance at this episode… [05:15] I dive into a simple overview of how to track your time and what information you need to know for every project to truly audit your time and calculate your profitability. [15:20 ] If talking about money makes you a little queasy, I share my story of working with Money Coach, Jenny Karlsson to change my mindset and help build a business that would last.  [17:50] What do you do if your projects aren't profitable? I share a few strategies to help with this.  [27:30] I share my challenge for you this week on auditing your projects to make sure you are able to increase profitability and build your own business that lasts. EDIT: In today's episode I used the term Total Project Cost but what I should have said was Total TIME Cost. The reason is, Total Project Costs would include additional costs such as client gifts, meals, paying for mistakes, etc.  When you are auditing a project's profitability, you're going to also want to look at sales for products as well as project related costs. But Since in this episode we are only focused on TIME, I should have said Total Time Cost or TTC vs TPC. The calculations are all still the same but I wanted to correct my terminology here. When you download the PDF you will see the correct term, “Total Time Cost or TTC” in the formula. Resources mentioned in this episode:  Book:  Money Magic by Deborah L. Price Jenny Karlsson - FInancials for Creatives  Episode 9 - How hiring can help your bottom line   FREEBIE: Project Audit PDF

Golf Smarter Mulligans
Group Conversation with Jeff Ritter LIVE at Golf Smarter Scottsdale Adventure

Golf Smarter Mulligans

Play Episode Listen Later Aug 19, 2022 46:20


172: Jeff Ritter breaks bread with host Fred Greene and listeners at our weekend of fun and golf in Scottsdale Arizona for our Golf Smarter Adventure 2011. Jeff answers questions from the group about game improvement, talks about his someone in Korea who has learned how to swing a golf club just by watching Jeff's YouTube videos, and more.

The Create Your Own Life Show
Rich Baris | The People's Pundit, Understanding Polling and Looking at the 2022 Mid-Terms

The Create Your Own Life Show

Play Episode Listen Later Aug 9, 2022 47:50


About This Episode: Richard D. Baris is the Director of the Big Data Poll, and is the Data Journalism Editor at People's Pundit Daily (PPD). He is a dedicated political blogger and also writes for the media wing of TPC - the Tea Party Tribune. Rich has been a political academic, speaker, journalist and financial advisor, and served in the United States Army after being recruited under the 18X-Ray Special Forces program. Rich authored the must-read book on American political philosophy, 'Our Virtuous Republic: The Forgotten Clause in the American Social Contract'. He is a former bad-guy-turned-good only by the grace of the Almighty Creator and has been married to one beautiful wife with two beautiful children.   Find out more about Rich at: PPD Website: https://www.peoplespunditdaily.com/ People's Pundit Community: http://peoplespundit.locals.com/ LinkedIn: https://www.linkedin.com/in/richardbaris/ Facebook: https://www.facebook.com/PeoplesPunditDaily Twitter: https://twitter.com/Peoples_Pundit YT Channel: https://www.youtube.com/c/PeoplesPundit/ Check out our YouTube Channel: Jeremyryanslatebiz See the Show Notes: www.jeremyryanslate.com/1009 Unremarkable to Extraordinary: Ignite Your Passion to Go From Passive Observer to Creator of Your Own Life: https://getextraordinarybook.com/ Sponsors: Gusto: This episode is sponsored by Gusto. Run your payroll the easy way, the same way we do at Command Your Brand. You'll get a. $100 Amazon Gift Card just for running your first payroll! http://www.jeremyryanslate.com/gusto MyPillow: Use the promo code: CYOL to get up to 60% off https://www.mypillow.com/ Audible: Get a free 30 day free trial and 1 free audiobook from thousands of available books. Right now I'm reading " Bad News How Woke Media Is Undermining Democracy" by Batya Ungar-Sargon www.jeremyryanslate.com/book  

numberFire Daily Fantasy Podcasts
The Heat Check: PGA FedEx St. Jude Championship 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Aug 9, 2022 19:36


The PGA Tour's FedEx Cup Playoffs get underway at TPC Southwind this week for the FedEx St. Jude Championship. What quirks does the course hold, and how should the playoff standings impact our process? Brandon Gdula breaks all that down and more to help narrow down the best FanDuel daily fantasy golf plays of the week.

Sports to the Max with Mike Max
Sports To The Max: Chris Weinhold

Sports to the Max with Mike Max

Play Episode Listen Later Jul 22, 2022 9:37


The first round of the 3M Open in Blaine got underway today. Chris Weinhold, GM of the TPC in Blaine joins Mike Max to discuss day one of the tournament.

numberFire Daily Fantasy Podcasts
The Heat Check: PGA 3M Open 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Jul 19, 2022 69:59


A top-heavy field heads to TPC Twin Cities for this week's 3M Open. How does that field composition alter our approach for daily fantasy? numberFire's Brandon Gdula and Jim Sannes preview the event, discussing roster construction, how they're handling the top three golfers, and which mid-tier and value options on FanDuel could pop.

THE PRIMROSE CHRONICLES
Kum-By-Yah on the Banks of Lake Galilee

THE PRIMROSE CHRONICLES

Play Episode Listen Later Jul 18, 2022 28:58


Camp Allendale  as a summer church camp was representative of similar faith-based operations across the Midwest in the mid-twentieth century. This episode of TPC pays tribute to its culture and impact on the young lives, including your host and narrator's, as they attended annually during their Junior High  and HighSchool years. Though the narrative is more details than tales,  it should still bring smiles through personal recollections.Enjoy & blessings!!!

Leandro Twin
Curso Sobre Esteroides Anabolizantes *Não use nada sem antes fazer este curso* (link na descrição)

Leandro Twin

Play Episode Listen Later Jul 11, 2022 2:34


Novo Curso Sobre Esteroides Anabolizantes: https://hotm.art/mM6K0Gy O curso se destina a qualquer pessoa sem conhecimento prévio sobre esteroides anabolizantes (EAs), que se interesse pelo meio fitness, sendo profissionais da área ou não, e que tem interesse em saber mais sobre o uso dos esteroides anabolizantes no fisiculturismo profissional e amador: Você vai entender mais sobre os potenciais efeitos anabólicos e androgênicos de cada esteroide anabolizante, todos os prós e contras do uso sendo homem ou mulher, e todos os perfis de EAs mais usados para o ganho de massa muscular no fisiculturismo. Passarei noções básicas para você entender o que é "meia-vida", "ésteres", "anabolismo", "androgenismo", e muito mais. Você vai entender e conhecer os ciclos mais usados por profissionais e amadores. Todos os detalhes referentes as fases de dieta e treino em conjunto com o uso dos EAs. Quem pode usar e quem não pode, exames, acompanhamento, terapia pós ciclo (TPC), e muito mais. As aulas ficam disponíveis 24hs por dia, 7 dias por semana, e você pode acessar do seu celular no app Hotmart Sparkle. A duração total do curso é de um pouco mais de 5 horas e o acesso é de 1 ano. Após a conclusão, o aluno recebe o seu certificado (somente um por plano) na própria plataforma da Hotmart. É preciso solicitar direto do seu computador, pois no app Hotmart Sparkle não tem esta função. Aproveitem com consciência. Bom curso! Atenção: As mensagens contidas em todos os vídeos de LeandroTwin não possuem o objetivo de substituir orientação de um profissional (independente da sua área de atuação). O vídeo é informativo. Qualquer rotina iniciada por conta própria é de responsabilidade do próprio.

Rob Dibble Show
TPC River Highlands GM David Corrado

Rob Dibble Show

Play Episode Listen Later Jun 30, 2022 14:45


The Rob Dibble Show was live from the Travelers Championship in Cromwell Connecticut. The General Manager of the TPC River Highlands join Rob and Ben to discuss all that goes into the preparation for Championship week!

Leandro Twin
Curso Sobre Esteroides Anabolizantes *Não use nada sem antes fazer este curso* (link na descrição)

Leandro Twin

Play Episode Listen Later Jun 30, 2022 2:31


Novo Curso Sobre Esteroides Anabolizantes: https://hotm.art/mM6K0Gy O curso se destina a qualquer pessoa sem conhecimento prévio sobre esteroides anabolizantes (EAs), que se interesse pelo meio fitness, sendo profissionais da área ou não, e que tem interesse em saber mais sobre o uso dos esteroides anabolizantes no fisiculturismo profissional e amador: Você vai entender mais sobre os potenciais efeitos anabólicos e androgênicos de cada esteroide anabolizante, todos os prós e contras do uso sendo homem ou mulher, e todos os perfis de EAs mais usados para o ganho de massa muscular no fisiculturismo. Passarei noções básicas para você entender o que é "meia-vida", "ésteres", "anabolismo", "androgenismo", e muito mais. Você vai entender e conhecer os ciclos mais usados por profissionais e amadores. Todos os detalhes referentes as fases de dieta e treino em conjunto com o uso dos EAs. Quem pode usar e quem não pode, exames, acompanhamento, terapia pós ciclo (TPC), e muito mais. As aulas ficam disponíveis 24hs por dia, 7 dias por semana, e você pode acessar do seu celular no app Hotmart Sparkle. A duração total do curso é de um pouco mais de 5 horas e o acesso é de 1 ano. Após a conclusão, o aluno recebe o seu certificado (somente um por plano) na própria plataforma da Hotmart. É preciso solicitar direto do seu computador, pois no app Hotmart Sparkle não tem esta função. Aproveitem com consciência. Bom curso! Atenção: As mensagens contidas em todos os vídeos de LeandroTwin não possuem o objetivo de substituir orientação de um profissional (independente da sua área de atuação). O vídeo é informativo. Qualquer rotina iniciada por conta própria é de responsabilidade do próprio.

numberFire Daily Fantasy Podcasts
The Heat Check: PGA John Deere Classic 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Jun 28, 2022 63:30


This week's John Deere Classic features a wonky field with no clear-cut studs at the top. How does that alter our approach to PGA DFS? numberFire's Brandon Gdula and Jim Sannes preview the event, discussing intricacies of TPC Deere Run, which of the studs we should trust, and optimal roster construction for FanDuel lineups.

numberFire Daily Fantasy Podcasts
The Heat Check: PGA Travelers Championship 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Jun 21, 2022 70:58


The PGA Tour sends a top-heavy field to TPC River Highlands for this week's Travelers Championship. How does that impact our roster construction for FanDuel lineups? numberFire's Brandon Gdula and Jim Sannes preview the event, discussing the intricacies of the course, optimal approaches to building lineups, and the top golfers in each salary tier.

ASCO Daily News
DESTINY-Breast04 and Other Key Breast Cancer Studies at ASCO22

ASCO Daily News

Play Episode Listen Later Jun 21, 2022 31:01


Dr. Allison Zibelli, of the Sidney Kimmel Cancer Center – Jefferson Health, and Dr. Hope Rugo, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discuss the practice-changing DESTINY-Breast04 trial as well as novel therapies in metastatic HR+/HER2- breast cancer from the TROPiCS-02 and MAINTAIN studies, all of which were featured at the 2022 ASCO Annual Meeting.   TRANSCRIPT Dr. Allison Zibelli: Hello. I'm Dr. Allison Zibelli, your host for the ASCO Daily News Podcast today. I'm a vice-chair and breast medical oncologist at the Sidney Kimmel Cancer Center, Jefferson Health in Philadelphia. My guest today is Dr. Hope Rugo, a professor of medicine and the director of Breast Oncology and Clinical Trials Education at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. We'll be discussing key advances in breast cancer that were featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the show notes, and disclosures of all guests on the podcasts can be found on our transcripts at asco.org/podcasts. Hope, it's great to talk to you today. Dr. Hope Rugo: Nice to talk to you, too. Dr. Allison Zibelli: Let's begin with perhaps the most exciting abstract at ASCO this year, which was the DESTINY-Breast04 study, that's LBA3, a randomized phase 3 study of trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-low, unresectable and/or metastatic breast cancer. What are your thoughts about this study? Dr. Hope Rugo: Well, of course, this is a hugely practice-changing study as was noted in the second-to-last slide by the discussant [Dr.] Pat LoRusso. So, antibody-drug conjugates are really the next step in delivering chemotherapy to cancer cells. The antibody-drug conjugates allow targeted delivery of a toxin to the cancer cell. I think we didn't understand how important this was going to be. These second, sort of, verging on third-generation antibody-drug conjugates use an antibody approach and to then have a new generation of linkers, which allow the drug to be released locally, but to then have drugs which pack a big bang for the buck. So, the way antibody-drug conjugates are constructed, you need to have a drug that actually can't be given as a naked drug because it's too toxic because you're giving just very small amounts of this drug that are delivered directly to the cancer cell. And the other really critical part of this is that the drug-to-antibody ratio of at least the successful and new antibody-drug conjugates (ADC) is quite high in the 7.5 to 8 toxins per antibody. Now, what that's resulted in is really interesting, is that there's a bystander effect. So, the toxin itself can leak out of the cancer cell that it's targeted and kill neighboring cells, but also because of the construct of these antibody-drug conjugates, what's likely happening is even if the cancer cell's a very low expression of the target, really low, you're able to actually get that ADC into the cancer cell to kill the cancer cell. So that may be a big part of the so-called bystander effect. So trastuzumab deruxtecan is biosimilar trastuzumab linked to a topoisomerase inhibitor deruxtecan, and what happened here was that of course, we saw remarkable data in HER2+ disease, unbelievable p-values in DESTINY-Breast03 compared to T-DM1, a first-generation ADC. But in DESTINY-Breast04, we targeted a population of patients largely with hormone receptor-positive disease who had a little expression of HER2, 1 plus or 2 plus by immunohistochemistry and no gene amplification. And this trial, which randomly assigned patients 2:1 and included just 58 patients with triple-negative disease. So in this trial, 480 had hormone receptor-positive breast cancer, a median of 1 line of prior chemotherapy. They were only allowed up to 2. They were refractory to endocrine therapy, a median of 3 lines of endocrine therapy. In the overall patients and in the hormone receptor-positive patients, there was actually a doubling in progression-free survival (PFS). It started very early, and it continued throughout, and at every landmark analysis, T-DXd was better than the treatment of physician choice that patients were randomly assigned to. It's also important when you're thinking about trials like this to think about what the treatment of physician choice was, and it was all chemotherapy regimens we would use. Paclitaxel, nab-paclitaxel, capecitabine, eribulin, or gemcitabine. And, so, I think that that doesn't bring up any questions. When they looked at the hormone receptor-positive group, they saw, if anything, even a bigger benefit overall. Now, the other endpoint of this trial was overall survival, and at this first analysis, they saw an improvement in overall survival that was quite dramatic. The absolute difference was 6.4 months, which is pretty amazing for an overall survival difference. And then they looked at this exploratory endpoint at the 58 patients who were valuable at triple-negative breast cancer, and then that group of patients, also saw an improvement in PFS of 5.6 months, an improvement in overall survival of 9.9 months, very small group, but amazing data. The forest plots are exactly what you want to see, all the dots line up to the left of 1, and overall responses improved. One of the concerns with this drug has been toxicity. The toxicity showed no new toxicity signals, which is really important. Nausea is the biggest issue that we deal with. It's mostly grade 1 and 2, but still something that's important to manage. A little bit of hair loss, not much in the way of bone marrow suppression, which is interesting. Interstitial lung disease (ILD) or pneumonitis continues to be an important issue to follow. 12% of patients had ILD of any grade. Most of it was grade 1 and 2, but 3 patients died, representing 0.8%. So, this really highlights the importance of monitoring and managing pneumonitis. Regardless of that, few patients had a reduced ejection fraction, but again, very, in general, low grade. This is really a new standard of care, and the standing ovation was really due to the fact that all we do is dedicate ourselves to trying to help patients live longer and better with their cancers, and in this trial, we have a huge win that has no qualifications. We can help patients not only control their disease longer but live longer with T-Dxd compared to standard chemotherapy. Dr. Allison Zibelli: So, Hope, I know as a practicing medical oncologist, I find that our metastatic triple-negative patients are often the biggest therapeutic challenges for us. Will they be doing larger studies with these patients that are HER2-low? Dr. Hope Rugo: It's a really good point. About 65% of patients with hormone receptor-positive disease or so-called HER2-low, centrally confirmed in the study. So, a fair number of people, about a quarter, did not have HER2-low disease when they were tested centrally. In the triple-negative population, who really are ER, PR, HER2- by standard definitions, about a third of the patients might have HER2-low disease. So, there's a lot of interest in further exploring that and looking at the patients who have ultra-HER2-low disease, so between and 1 plus a little bit of expression. That's been studied in the hormone receptor-positive population in DESTINY-Breast06. But there's a lot of interesting further defining that triple-negative population, so to speak, they're going to be triple-negative plus now and understanding what the benefit is in that population. So definitely will be looked at more now moving forward. Dr. Allison Zibelli: Thank you. So, let's move on to Abstract 1002. And the results from the phase 1, 2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate, and patients with HER3 expressing metastatic breast cancer. What are your thoughts about this study? Dr. Hope Rugo: That's a really interesting, another one of these second- to third-generation antibody-drug conjugates. It's just the antibody, instead of being the usual, sort of, HER2 or TROP2 that we're used to thinking about is directed to HER3, 1 of the HER family of proteins. This is interesting. There's actually been a lot of work trying to target HER3 with naked antibodies with disappointing results, although I have to say most of the studies really didn't push it too far. So, with this antibody drug construct, deruxtecan, which is the same as in T-DXd and another TROP2 ADC Dato-DXd is used. So, I will say they do need to change the toxin in the next generation of ADCs. But they looked at, at first did a dose-finding study which has previously been presented, and then a dose expansion in both hormone receptor-positive HER2-negative disease and triple-negative disease. All the triple-negative patients had HER3 high disease by immunohistochemistry, and the hormone-receptor-positive patients were enrolled in 2 cohorts, HER3 high and HER3 low. And the median number of prior treatment regimens that patients had received in the hormone-receptor-positive group was 6 and 2 for the triple-negative group, but there was a huge range, up to 13 lines of treatment. They only had 14 patients with HER2+ disease. So, it's a little bit hard to know what to do with that patient group, but they were heavily pretreated 5.5 prior lines of therapy. The confirmed overall response rate in the 113 patients with combined HER3 high and low was 30%, very impressive, heavily pretreated patients. For triple-negative disease all HER3 high, it was 23%. Again, very nice. And there were 14 patients with HER2+ disease that also were HER3 high. It was about 43%. So those are nice responses, but we always want to know how durable is that. The duration of response ranged from 6 to over 8 months in those 3 different groups. So, these were quite durable. It wasn't any 2- to 3-month duration of response. So very impressive. And then when they looked to see, did it matter whether you had HER3 expression that was high or low in the hormone-receptor positive group, they actually did see responses in the HER3-low group, some very good responses. Overall, there were less patients in that group, but it does suggest that maybe you would still see responses in the HER3-low group, very impressive. And then 1 really interesting correlative study they did was they looked to see what happened to the HER3 expression on the tumor cell over time, and it went down. So, you treated the HER3 expression in most of the patients just dropped off completely, which is really interesting. It didn't have any association with clinical activity, but it's sort of an interesting correlative endpoint. This is a drug that overall was pretty well tolerated. They saw a similar toxicity to T-DXd with a lot of nauseous, a little bit of alopecia, a little bit more bone marrow suppression than we're used to seeing with T-DXd. So, neutropenia was seen in about 10% of patients at the lower dose and about a quarter of the patients at the higher dose. Overall, pretty well tolerated. Now, interstitial lung disease is a toxicity with this construct, and they saw ILD of 7% but most cases were grade 1 and 2. The other interesting toxicity that's unique to this agent is thrombocytopenia. So, they saw a grade 3 or greater rate of thrombocytopenia of 27% in the lower dose group, and in the larger group that received the higher dose, 39% of grade 3 or greater thrombocytopenia, so platelets less than 100,000. Turns out that when you stop the drug, the platelets do come back, so that's a good thing. Sometimes we saw long-term thrombocytopenia with T-DM1. They didn't see bad toxicity like bleeding, but it is something that needs to be managed with this drug because we're not great at managing thrombocytopenia. In any case, it has fast-track designation for another solid tumor, not breast cancer, and we'll have to see where this fits into our dizzying array of very effective ADCs now. Dr. Allison Zibelli: The practicing medical oncologist is not used to testing for HER3 in our patients with breast cancer. How common is it? Dr. Hope Rugo: HER3 expression is quite common in hormone receptor-positive disease, a little less common in triple-negative breast cancer. So, I think that we would see expression if we were going to be treating patients with this particular approach. Dr. Allison Zibelli: All right. Let's move on to Abstract 507, which reported long-term outcomes of adjuvant denosumab in breast cancer, specifically fracture reduction and survival results from 3,425 patients in a randomized double-blind, placebo-controlled ABCSG-18 trial. What are your thoughts about this study? Dr. Hope Rugo: Well, this trial, this is an update of a study that previously has been presented and published, most recent publication was in Lancet Oncology in 2019, and these patients were randomly assigned to receive denosumab at 60 milligrams, important to note the dose, subcutaneously every 6 months versus placebo every 6 months, and they did get placebo subcutaneous injections. And this treatment continued through their endocrine therapy. They showed a dramatic reduction in fracture rate, and that has been maintained over time. We were really surprised enough to suggest that maybe Austrian people didn't go into the sun, so they got more Vitamin D deficiency, hard to know, but the hazard ratio is 0.5. It's unbelievable the number of fractures, 92 for denosumab but 176 for placebo, a P value of less than .0001. So, this is a real endpoint, treating patients who are receiving endocrine therapy that, in this case, non-steroidal aromatase inhibitor therapy that can increase bone loss, have a reduced fracture rate when they received denosumab. So that is the big take-home message, and a medium follow-up of 8 years. But the secondary endpoints included disease-free survival. They had about 20% disease-free survival events and 8% deaths, and what they saw was really interesting. So, the caveat is that 16% of patients were unblinded at the first analysis and half of them got denosumab, so it messed up their results a little bit, but the disease-free survival was significantly better in patients who received denosumab, and the hazard ratio of 0.83 and the hazard ratio does not cross 1. So that's very interesting, and even overall survival, they looked at 2 other endpoints, bone metastasis-free survival, and overall survival. They also trend towards an improvement with a hazard ratio of 0.8 for both of them. And they didn't actually see toxicity. So, patients' brittle bone fractures and osteonecrosis of the jaw (ONJ) are all concerning, but they really just did not see any risks in this patient population. I think there was 1 patient that had what they thought was a brittle bone fracture. Obviously, they watched the mouth very carefully as well. Really dramatic, and I think it's kind of disappointing that we never had any registration approach in this, and also not well-understood why the D-CARE study did not show a benefit, but I think D-CARE was designed differently. This is a better design to focus on our patients and the specific issues, and I think it's intriguing and should be considered as part of our treatment regimen for patients who are at risk for bone loss and have early-stage breast cancer on an aromatase inhibitor. Dr. Allison Zibelli: I've been using DEXA scans and offering denosumab to my patients on AIs that have osteopenia or osteoporosis. Should we be considering it in women with normal bone mass? Dr. Hope Rugo: I think not yet. Unfortunately, this trial was not immediately powered for cancer outcome, although the data are very encouraging. We don't know what the relationship is to bone loss, and providing an environment that's friendlier for cancer cells. So, do you have to have bone loss in order to have the risk that you're reducing with these agents? Certainly, that's what we've seen with zoledronate. So, I think that we don't have sufficient data to use this simply to treat cancer, but I do think that we should be considering this as an agent to give patients who have bone loss, either when you're starting an aromatase inhibitor or during the course of therapy. I think it's well tolerated, and a subcutaneous injection is not difficult. One of the questions that's come up for people is do you get bone loss that increases your risk of fracture after you stop therapy. But clearly from these updated data, these patients were off therapy. They did not have an increase of fractures and the patients treated with denosumab fared much better, I mean the hazard ratio of 0.5. Dr. Allison Zibelli: Let's move on to TROPiCS-02. That's LBA1001. This is a randomized phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with hormone receptor-positive, HER2-negative advanced breast cancer. How do you think this study will impact practice? Dr. Hope Rugo: That's a great question. I presented this data, and I think I presented it on a Saturday, and on Sunday we saw the plenary talk of DESTINY-Breast04. These patients enrolled in TROPiCs-02 had a median number of lines of prior chemo 3 with a range of up to 8 actually, compared to a median number of lines as 1 in the DESTINY-Breast04 population. We included all hormone receptor-positive HER2 negative-advanced breast cancer, not centrally confirmed. They included just the HER2 low subset that was centrally confirmed. Everybody in our study had received prior CDK4/6 inhibitors compared to about 70% in DB04. And then 95% of patients in this trial had visceral mets. So, we did really treat a patient population who had very advanced high risk hormone receptor-positive breast cancer. As you know, we saw an improvement and progression-free survival with a hazard ratio of 0.66 meeting the endpoint. We needed a hazard ratio of 0.7, highly statistically significant P value .0003, but the median difference in PFS was only 1.5 months, and overall survival data is not yet mature. So that's brought up the question about how this drug should be used because there was a big fall off in the first 2 months where patients had rapid disease progression with heavily pretreated chemotherapy-resistant disease. We did landmark analyses and there were big separations in PFS at 6, 9, and 12 months, and 12 months, it was 21% patients free of progression and death at 1 year versus 7% for the TPC arm. So, it was a tripling of patients who were free of progression at one year. I think that's clinically relevant. This drug is associated with more neutropenia. That's the primary issue to manage, and probably half of the patients need growth factors at some point. When we looked at other endpoints response to ratio response, etc., we're better with Sacituzumab. So where does this all fit into our treatment paradigm. I think there's the HER2-low patients who will now receive T-DXd up in the, I hope, second line and not in lieu of endocrine therapy, when they're ready for chemo. But there are patients who don't have HER2-low disease and then there are patients who are going to be in the later line setting. So, I do think it still has a place in the treatment department, receptor-positive metastatic breast cancer. The results show that it was better than chemotherapy, physician choice based on our national and international guidelines, and that's better for our patients to have that option. Overall survival data obviously is looked for with great interest and that will help us put this into the right paradigm. And then I also hope that real world data will help us understand how sequential treatment with these different ADCs will benefit our patients. Dr. Allison Zibelli: This is really exciting. Do you think that we're maybe coming toward the end of conventional chemotherapy, especially for women with HER2-positive disease? Dr. Hope Rugo: I wonder if we are. I think we were interested in T-DM1 for HER2-positive disease early on. We've seen some really nice pathologic complete response data as well as adjuvant data in the attempt trial in patients who had stage I disease. Now that we have these second-, third-generation ADCs, T-DXd, I think this could potentially completely replace our chemotherapy. We still have to deal with alopecia. And I will point out ADCs are still chemotherapy. They're just a much more efficient and effective way of delivering treatment, and we need to be very careful to manage the toxicity. Dr. Allison Zibelli: Next, we're going to talk about the main pain trial that's LBA1004, which is a randomized phase 2 trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or hormone receptor-positive HER2-negative metastatic breast cancer, in other words CDK4/6 after CDK4/6. What are your takeaways here? Dr. Hope Rugo: First, just amazing that an investigator-initiated trial could do this well and be placebo-controlled. So, kudos to the principal investigator (PI) [Dr.] Kevin Kalinsky. This trial is a small phase 2 trial. A reasonable number, 119 patients were randomly assigned and evaluable patients could have received up to 1 line of prior chemotherapy for metastatic disease. If you had received prior exemestane, you received fulvestrant, if you received prior fulvestrant, you received exemestane, and actually if you looked at the number of patients who had received fulvestrant, it was 99 versus only 20 with exemestane. So important to keep in mind. If you looked at the overall population where the primary endpoint was progression-free survival, the hazard ratio is 0.57, just median PFS of 2.8 months in patients receiving endocrine therapy and placebo and 5.3 months for patients receiving endocrine therapy and ribociclib. So was this ribociclib after ribociclib or ribociclib after something else. 86% of patients had received palbociclib as their prior CDK4/6 inhibitor, and only about 10% to 14% had received prior ribociclib. So, there's a predominance of palbociclib followed by ribociclib. The other thing that's important to keep in mind is how sick this patient population was. Very few had received prior chemotherapy in the less than 10% range, visceral metastases in about 60%. So that's helpful. Only 19% or so had received 2 or more endocrine therapies from metastases. So, most people did this as their second line treatment. The PFS, when you looked at fulvestrant or exemestane, looked like the benefit was relatively similar, but you know you got 20 patients in the exemestane arm. The hazard ratios, looking at the subgroup analyses, all looked pretty similar, and the overall response and clinical benefit rate were better with continuing the cyclin dependent kinases (CDK) inhibitor. There was interesting sub-analysis looking at mutations and how that affected things. And they looked at patients who had ESR1 mutations or had wild-type ESR1. 42% had ESR1 mutations at study entry, very similar to what we've seen. In that group of patients, remember it's only 33 where they had this analysis, they saw a lot of other mutations. So p53, PIK3CA, FGFR, CCND1—those patients did not benefit. Only 33 patients. No benefit at all, very short PFS, about 3 months. The patients who had ESR1 wild type seemed to benefit a lot, 45 patients going from about 3 months to a little over 8 months. So, this is all hypothesis-generating data. I wouldn't run out and use this as your standard of care now because it is small data. But when the patient doesn't have other good options, I certainly would consider switching the CDK and going on, add that to the next line endocrine therapy. It's important to switch the endocrine therapy. I think we really need to look at the ongoing phase 3 trials to give us better evidence basis and understand the impact of mutations and prior therapy on who might benefit from continued CDK inhibitors after progression on a CDK inhibitor. Dr. Allison Zibelli: I think this is a really exciting trial. We all have a lot of patients on palbociclib and letrozole who've been on for 4, 5 years, and would like to continue with this kind of treatment because the side effects are really manageable. So, I look forward to seeing what's coming in the future with the phase 3 trials. So, let's talk about Abstract 1015, which I thought is a great idea. It looks at the quality of life with ribociclib plus aromatase inhibitor versus abemaciclib plus AI as first-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer, assessed via matching adjusted indirect comparison. Could you tell us what matching adjusted indirect comparison is and why you chose this for the study? Dr. Hope Rugo: It's an interesting question. How do you compare across trials? So, matching this kind of make analysis, we'll call it a make analysis for the purposes of this discussion, allows you to match patients and weight based on their characteristics that might affect patient reported outcomes. And that actually is a way of trying to do a fair cross-trial comparison. So basically, take the study population, you match the inclusion and exclusion criteria, and then you weigh the different criteria so that you can try and make a better association. It's the best way we know of comparing across trials. You know, a lot of people ask why we didn't have PALOMA-2 in here, and that's because they used a different patient reported outcome tool. So, you have to use the same patient reported outcome tool in order to compare. So that's why we did this analysis, and it sort of came on the heels of a survey that Fatima Cardoso presented at San Antonio in 2021, where patients identified diarrhea as a symptom they really didn't like more than everything else. And you can imagine, I think we all have that experience in practice, the unexpected nature of diarrhea and the fact that it does limit your activities and, therefore, quality of life are important. In this analysis, interestingly but not surprisingly, ribociclib favored abemaciclib in diarrhea, and there can be associated appetite loss, so ribociclib also favored abemaciclib for appetite loss. And I thought the last one was interesting—fatigue—because I wouldn't have assumed that fatigue would be different. And maybe it's associated with diarrhea. They have these funny arm symptoms that were better. We don't really know why that was, and it's hard to assess again. We're really not clear based on the differences between the drugs. So, there are limitations to the analysis, but I think that it helps us really in individual patients try and match patients' underlying symptoms with the best treatment to offer them the best quality of life as they're being treated in the metastatic setting. Dr. Allison Zibelli: I thought this study was great because it really centered the experience of the patient and the wishes of the patient. You don't see that designed into many clinical trials, the way this was. So, I thought that was a great feature of this study. Dr. Hope Rugo: I will say that all of the 3 studies that looked at CDK inhibitors, all those 3 studies included patient-reported outcomes. That's an important new approach that is really being focused on. Dr. Allison Zibelli: Do you consider the CDK4/6 inhibitors equivalent in efficacy, and could you substitute them to try to get the side effect profile that you want? Dr. Hope Rugo: Well, I think that we saw in the early stage setting that there are differences. Now, across the different trials, there are big differences in patient populations and inclusions as we saw in the PALOMA-2 results that were presented at ASCO [Annual Meeting], whether the patients had prior chemotherapy like in PALOMA-3, whether they had a short disease-free interval, the higher risk patients in PALOMA-2. The PALOMA trials were more broadly inclusive than the other 2 studies, the MONALEESA and MONARCH series of trials. So, we do have to be a little bit careful about comparing apples to oranges, but we have the early-stage results of MONARCH E showing a clinically important difference in outcome whereas the PALLAS and Penelope-B trials didn't. So that sort of puts us into a little bit of a question period. Are these all patient populations or are there differences between the agents? The PFS and the metastatic setting, all the hazard ratios line up. So, in truth, although I know the activity against cyclin-independent kinases are different between agents, we don't still really understand the clinical differences in efficacy, but I think we all are practicing using evidence-based medicine. I wouldn't, for example, substitute a different CDK4/6 inhibitor for abemaciclib in the treatment of early-stage breast cancer. We have to just learn how to manage the diarrhea and use prophylaxis and dose reduce early to manage this and make it tolerable for our patients. And in the metastatic setting, I think we need to follow evidence-based guidelines and use the best data available to decide on the right treatment approach and sequencing for our patients. Dr. Allison Zibelli: Thank you, Hope, for coming on the podcast today. This was a really interesting review of one of the most exciting ASCO [Annual Meetings] I've been to. And thanks for sharing your valuable insights with us and helping us make sense of all this really new exciting data. We really appreciate it. Dr. Hope Rugo: Thank you. And thank you so much for inviting me. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You will find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. That really helps other listeners find us. Thank you.   Disclosures: Dr. Allison Zibelli: None disclosed. Dr. Hope Rugo: Honoraria: Puma Biotechnology, Mylan, Samsung Bioepis, Chugai Pharma, Blueprint Medicines Consulting or Advisory Role: Napo Pharmaceuticals Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Odonate Therapeutics, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Ayala Pharmaceuticals, Astellas Pharma, Seattle Genetics, Macrogenics, Boehringer Ingelheim, Polyphor Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

It's Super Effective: A Pokémon Podcast
Top Grossing Media Franchise in the World

It's Super Effective: A Pokémon Podcast

Play Episode Listen Later Jun 20, 2022 57:56 Very Popular


Where does all that money the Pokémon Company come from? We talk about the break dow of revenue TPC makes compared to other big bands like Super Mario, Hello Kitty, and Star Wars.  We talk about the PokéToons coming to the US, a Pokémon Center update, and a Pokémon GO update. 00:00:20 - Introduction00:04:30 - Video Game Sales00:07:10 - Most Successful Media Franchises00:22:20 - Pokémon Center Update00:28:00 - PokéToon00:30:00 - Break 00:32:00 - Pokémon GO News00:42:20 - Single Battle Cup00:44:00 - Question of the Week00:54:00 - Pokémon of the Week00:58:00 - Post Credits

Pat Mayo Experience
2022 Travelers Championship Picks + US Open Recap

Pat Mayo Experience

Play Episode Listen Later Jun 20, 2022 98:29 Very Popular


Pat Mayo and Geoff Fienberg preview the course and run through the odds while making their 2022 Travelers Championship Picks. The guys give their fantasy golf picks, provide their one and done strategy for the event from TPC river Highlands. RAKE FREE DraftKings Listeners League: https://bit.ly/22TravDKPMELL Get 20% All DK Tools/Stat Engine: https://www.fantasynational.com/mayo Get a deposit match up to $100 with first deposit at JOCK MKT with Code “MMN”: https://bit.ly/JOCKMKTMMN SHOW INDEX 00:00 Intro 1:56 US Open Recap 19:37 Coverage 24:02 LIV 38:37 US Open Wrap Up 48:55 Travelers Championship 51:57 Travelers Championship favs 1:00:09 30-60 1:10:26 60+ 1:26:42 Quick Picks + ONE AND DONE 1:31:21 BMW International Audio Podcasts Apple: http://bit.ly/PMEiTunes Spotify: https://goo.gl/VboemH

TPC Scottsburg, IN
Food Giveaways RTTP

TPC Scottsburg, IN

Play Episode Listen Later Jun 20, 2022 9:05


Food Giveaways RTTPPastor Jon speaking with Johnny and Mare Burns about the TPC Food Giveaways and Wellness Wednesdays at TPC.

THE PRIMROSE CHRONICLES
A Tribute To Dad

THE PRIMROSE CHRONICLES

Play Episode Listen Later Jun 16, 2022 30:59


This is The Primrose Chronicles - Father's Day edition and features is a warm and loving reminiscence  of one dad's wisdom, instruction and chivalry that left a lasting impact on the TPC host & narrator. The hope for this episode will be multiple salutes by many sons & daughters toward the men who led their homes, never perfectly but often selflessly. If you were blessed by such, thank God. If not, resolve in the wake of this listening to be such a dad & husband going forward. Enjoy & blessings. 

Pro Crastinators Podcast
Vaush & Phantom's Revenge Inside Baseball – The Pro Crastinators Podcast, Episode 306

Pro Crastinators Podcast

Play Episode Listen Later Jun 6, 2022 219:08


PCP Episode 306 – Vaush & Phantom's Revenge Inside Baseball ➤Full PCP Episode Playlist – https://goo.gl/mduhGw➤iTunes – http://bit.ly/PCPApplePodcast➤Google Play – http://bit.ly/PCPGooglePlay➤Spotify – http://bit.ly/PCPSpotify➤All PCP mp3s: http://www.theprocrastinatorspodcast.com/ Support the PCP on Patreon conglomerate empire society! https://www.patreon.com/TheProCrastinators Join the PCP Minecraft Server: https://www.patreon.com/PCPMinecraftPCP Highlights Channel: https://www.youtube.com/channel/UCNBP4BmPEbhRFPxkm60HAawBUY PCP SHIRTS & MERCH! https://teespring.com/stores/the-pro-crastinators https://www.redbubble.com/people/ProCrastinators/shop https://gumroad.com/theprocrastinators (radcon behind the scenes)TPC … Continue reading "Vaush & Phantom's Revenge Inside Baseball – The Pro Crastinators Podcast, Episode 306"

Talking.Golf
Gary & Rob on Gary's Men-2-Boyz Tour in the Dells, Steve Stricker, Harrison Ott and WIAA state golf admission charge

Talking.Golf

Play Episode Listen Later May 30, 2022 47:47


Wisconsin.Golf's Gary D'Amato and Rob Hernandez discuss Gary's Memorial Day weekend of golf in the Wisconsin Dells, Steve Stricker missing the Senior PGA Championship after contracting COVID-19, Harrison Ott's Vanderbilt team in the NCAA Championships, the WIAA boys state tournament, Cherokee Country Club's designation as a TPC course, and more.

THE PRIMROSE CHRONICLES
TELLING TALES OUT OF SCHOOL

THE PRIMROSE CHRONICLES

Play Episode Listen Later May 19, 2022 33:59


Telling Tales Out of School” walks the TPC listener thru the halls, peeking in the classrooms of IPS Elementary School #91 to meet the teachers (Grades 2-6) of your host & narrator. Even if you attended #91 in a different era or not at all, you'll probably catch a glimpse of instructors you had in the caricatures portrayed.Short on the subject matter learned and long on the experiences encountered this longer than usual installment should connect with anyone who had a public school education and should offer an enjoyable half hour to anyone longing for the simpler life.Blessings

1010XL Jax Sports Radio
The Drill w/Dan Hicken & Jeff Prosser live from the TPC 05 - 16 - 22

1010XL Jax Sports Radio

Play Episode Listen Later May 16, 2022 156:15


The Drill w/Dan Hicken & Jeff Prosser live from the TPC 05 - 16 - 22 by 1010 XL Jax Sports Radio

numberFire Daily Fantasy Podcasts
The Heat Check: PGA AT&T Byron Nelson 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later May 10, 2022 64:19


This week's AT&T Byron Nelson is the PGA Tour's final tuneup before next week's PGA Championship, and it brings a loaded field. Which golfers should we target with stiff competition at TPC Craig Ranch? numberFire's Brandon Gdula and Jim Sannes preview the event, discussing the star-studded top end, which mid-range golfers stand out, and value plays to help us jam in more elite golfers on FanDuel.

THE PRIMROSE CHRONICLES
A Tribute To Mom

THE PRIMROSE CHRONICLES

Play Episode Listen Later May 5, 2022 27:26


In this episode, Marty Young, host and narrator, has selected three experiences from literally scores involving himself and his mom, Dorothy Young, to share in a Mother's Day salute to her. They have been culled from his childhood and adolescent years to highlight a couple of her most endearing qualities.In doing so, he not only reiterates the influence she was on his life, but also reveals a bit of what made her so personal and available, thus loved deeply by her kids. In this thoughtful and sweet, yet humorous installment of TPC, the creator of this podcast hopes to prompt the listeners to share their own acclaim of their respective moms sometime in this Mother's Day weekend. It's the least we all can do. Blessings

Lets Grow Pulling
Ryan DeBroux Joins the Let's Grow Pulling Live Monday, May 2nd. And we are drawing more pulling line ups for the TPC.

Lets Grow Pulling

Play Episode Listen Later May 3, 2022 99:40


Ryan DeBroux Joins the Let's Grow Pulling Live Monday, May 2nd. And we are drawing more pulling line ups for the TPC. --- Send in a voice message: https://anchor.fm/beer-money-pulling-team/message Support this podcast: https://anchor.fm/beer-money-pulling-team/support

numberFire Daily Fantasy Podcasts
The Heat Check: PGA Wells Fargo Championship 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later May 3, 2022 24:05


The Wells Fargo Championship is a PGA Tour schedule mainstay, but we're faced with an uncommon course for the week. What does that mean for course history and the upcoming event? numberFire's Brandon Gdula breaks down the key stats at TPC Potomac, discusses the viability of heavy favorite Rory McIlroy​, and provides his favorite daily fantasy golf picks and bets for the week.

Shit Gets Deep
Shit Gets Deep - Episode 102 - Be a better person

Shit Gets Deep

Play Episode Listen Later May 2, 2022 107:52


Being a good person seems like it should be the simplest of goals to accomplish. And being mindful of a couple simple things seems like that will get the job done. However after this conversation, some of us… (The Pirate Chef in particular) couldn't help realizing that part of being a good person, is to continually be working on yourself. There are always improvements that can be made. NOW, did TPC spiral into uncomfortable introspection and a self-loathing puddle of regrets every step of the way while recording this episode while Just Scott just sat and watched? YEP! But change never comes from being comfortable, and having your ego in check and your mind focused on the positive things in life will go a long way to help all of us become that person we strive to be. So PLEASE be kind, spread love, be honest, and treat others the way you would like to be treated, and maybe just maybe we come out of this all right. CHEERS!!!You know we love our Luxe Bidet because we talk about it every episode! Here's a link to get you 10% off your order, we just installed the Luxe Bidet 185 plus (Chrome) in the studio and absolutely recommend it! https://luxebidet.com/?ref=MQy6k6SITVV7 Or use coupon code SHITGETSDEEPPODCAST10 at checkout

Athletes and Assets
S2E6- Sheldon Day and Amir Carlisle talk about financial lessons learned in the NFL, The Players Company, and the genesis of Bank DAO

Athletes and Assets

Play Episode Listen Later Apr 15, 2022 31:46


Sheldon Day is not your typical NFL Player. When he is not sacking NFL Quarterbacks, the 6 year NFL defensive tackle is probably in a meeting with his business partner and former Notre Dame standout wide receiver/teammate, Amir Carlisle, on the next big investment. Both Sheldon, Amir, along with Richard Sherman run The Players Company, which leverages the collective influence and purchasing power of professional athletes for access to business development, financial education and investment opportunities. In addition to investing, Amir is taking point on running Bank DAO, a Web3 vehicle of TPC that is striving to build financial literacy and opportunity amongst a growing community through a shared bank account. We chat about financial lessons learned in the NFL, the TPC, and why Bank DAO is the future of finance for many involved. Links:  Twitter and IG: @sheldonday_91, @solarbot3 LinkedIn: Sheldon Day, Amir Carlisle https://www.theplayerscompany.co/ Bank DAO Discord: https://discord.gg/mfrvajw2 Episode Breakdown:  0:00- Intro  4:05- Managing investments through an NFL season  7:40- Positive influences like Kelvin Beachum that exposed Shel and Amir to business  10:50- The formation of The Player's Company 19:50- Bank DAO explained- formation, goals  29:38- Shel and Amir's Playlist 31:00- Outro  I do not own the rights to this music (Drake- Headlines Instrumental)   --- Support this podcast: https://anchor.fm/a--and--a/support

Special Conditions - A Pokémon TCG Podcast

Special Conditions Podcast 106 Recording Date - 4/7/2022 Publish Date - 4/8/2022   We begin with our most budget friendly Card of the Week ever! Rapid Strike Malamar can be picked up on TCGPlayer for about a buck and it brings a serious competitive style to the table! It took second place in Liverpool and was able to hang with the likes of Arceus VSTAR, Mew VMAX, and Gengar VMAX! We profile a deck that can be assembled for under $35!   Totodile is our Art of the Week and we have some prime examples of different art styles! Our featured illustrators vary in experience and mediums and Totodile reaps the rewards. Make sure you check out our blog to see the cards for yourself!   Logan Paul is in the news again and we are all grossed out by it. We get through the topic and then needed a shower to wash his name out of our mouths.    Finally we talk about the upcoming Level 3 League Battle Decks which at $30 offer the easiest path to competitive play. Bringing a 3/3 V/VMAX line, TPC is pushing their value proposition of these decks to the limit! Card of the Week: Rapid Strike Malamar - https://bit.ly/SC106Malamar  Rapid Strike Malamar Deck Strategy - https://bit.ly/SC106MalamarDeck  Top Deck Academy - https://bit.ly/SC106TopDeck  Art of the Week: Totodile - https://bit.ly/SC106Totodile  Logan Paul Illustrator - https://bit.ly/SC106LoganPaul League Battle Decks - https://bit.ly/SC106LeagueDecks    TCG Player Support the show by shopping at TCGPlayer.com using this link - https://bit.ly/TCGPlayerAffiliate    Pokémon Professor Network Merch Store - https://bit.ly/PPNMerchStore    info@specialconditionstcg.com  Voicemail, Text, and Picture Line - 732-835-8639  https://linktr.ee/PokemonProfessorNetwork  http://specialconditionstcg.com http://pokemonprofessor.com  http://bit.ly/PokeProfNetPatreon  http://bit.ly/PokeProfNetFacebook  http://bit.ly/PokeProfNetTwitter  http://bit.ly/PokeProfNetYouTube  http://bit.ly/PokeProfNetInstagram  http://bit.ly/SCApplePodcasts http://bit.ly/SCGooglePodcasts http://bit.ly/SCGooglePlayMusic http://bit.ly/SCSpotifyPodcasts https://bit.ly/SCiHeartRadio  https://bit.ly/SCPodchaser    Music provided by GameChops and licensed through Creative Commons   ▾ FOLLOW GAMECHOPS ▾ http://instagram.com/GameChops http://twitter.com/GameChops http://soundcloud.com/GameChops http://facebook.com/GameChops http://youtube.com/GameChops http://www.gamechops.com   Intro Music Trapped In A Pokéball Dj CUTMAN and Belthesar GameChops - Ultraball http://gamechops.com/ultraball/  http://soundcloud.com/DjCUTMAN http://soundcloud.com/belthesar   Break Music He Walk - Furret / Accumula Town Remix  Dj Cutman http://soundcloud.com/djcutman  http://twitter.com/videogamedj  http://youtube.com/djcutman   TN Comics Break Music Battle with Gladion (Electro House Remix) VGR GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/videogameremixes    Outro Music Kanto Trainer Battle Mykah GameChops - Ultraball http://gamechops.com/ultraball/  https://soundcloud.com/mykah   Hosts Adam Tuttle Ken Pescatore   Producer Ken Pescatore   Executive Producer Tish Smith   Pokémon And All Respective Names are Trademark and © of Nintendo 1996-2021Pokémon Professor and Special Conditions are not affiliated with Niantic Inc., The Pokémon Company, Game Freak or Nintendo   #pokemon #pokemontcg #podcast

numberFire Daily Fantasy Podcasts
The Heat Check: PGA Valero Texas Open 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Mar 29, 2022 59:48


This week's Valero Texas Open is the PGA Tour's final warm-up before they head to The Masters. Which golfers could enter Augusta on a high note? numberFire's Brandon Gdula and Jim Sannes preview the event, discussing the unique challenges of TPC San Antonio, optimal roster construction, and the top golfers in each salary tier on FanDuel.

The 73rd Hole
Scheffler Wins Again!! Talor Gooch Interview!!

The 73rd Hole

Play Episode Listen Later Mar 28, 2022 97:37


Scheffler wins match play, moves to No. 1 in the world Biggest surprises from Austin Will Tiger play Augusta? Talor Gooch talks Augusta National, John Conrad, TPC, Saudi MUCH MORE!!

Pillow Talk with Megan & Sydney
Recovering from TPC

Pillow Talk with Megan & Sydney

Play Episode Listen Later Mar 22, 2022 44:48


We recap our full-force TPC week and Syd discusses her big move to ALA-bama! Let's chit-chat...follow us on IG: @pillowtalk_POD

The Bogey Golf Podcast
Cam Smith wins THE PLAYERS

The Bogey Golf Podcast

Play Episode Listen Later Mar 18, 2022 80:37


We recap the amazing finish at the players. Cam Smiths shot on 18, Gold Man, the grounds crew getting the course set up and the horrible weather

The Tony Kornheiser Show
“Just like Uncle Miltie”

The Tony Kornheiser Show

Play Episode Listen Later Mar 15, 2022 76:27


Tony opens the show by getting Spike Braun's bracket picks. Chuck Culpepper of the Washington Post phones in with his picks, Steve Sands of the Golf Channel calls in with his bracket and he also talks about the TPC, and Tony closes out the show by opening up the Mailbag. Songs : Bees Deluxe “I Smell Smoke” ; Cade Baccus “Strike Up the Band” Learn more about your ad choices. Visit podcastchoices.com/adchoices

Too Much Dip
Original Tom Brady Jokes And Brett's Investment Strategy

Too Much Dip

Play Episode Listen Later Mar 14, 2022 65:24


A bunch of NFL notes: TB back, Russ in Denver, Jerry's random child, Amari to the Browns, a very wild Players Championship, some Puck with Brett and more! NFL (13:10) NHL (41:00) TPC (50:40) Run It Back (1:01:36) Support Our Sponsors: DraftKings-Download the DraftKings Sportsbook app NOW, use promo code WASHED Headspace-Find some HEADSPACE at HEADSPACE DOT COM SLASH BANG and get one month FREE of their entire meditation library.

No Laying Up - Golf Podcast
NLU Podcast, Episode 530: Saturday Players Recap

No Laying Up - Golf Podcast

Play Episode Listen Later Mar 13, 2022 59:47


End of day 3, mid-round 2 live show update from the Killhouse, as we talk about JT's round, Bubba, and the glorious carnage from the 17th hole today at TPC. What happened to the Golden Man? Who is *actually* leading the tournament? When are we gonna finish? All that and a lot more.

The Tony Kornheiser Show
“Who ordered the Bombogenesis?”

The Tony Kornheiser Show

Play Episode Listen Later Mar 11, 2022 64:25


Tony opens the show by talking about how while spring has arrived in DC, there is a nasty wintry storm hitting the east coast this weekend. He also reads a few emails and talks about the tough conditions at the first round of the TPC. Jason La Canfora of CBS Sports calls in to talk about the big moves made in the NFL this week, Ron Darling phones in to talk about the end of the owners's lockout and baseball's new labor deal, and Tony closes out the show by opening up the Mailbag. Songs : Mike Stocksdale “Wishes and Wants” ; Dan Bern “The DH Song” Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Tony Kornheiser Show
“The Lemonhead Caper”

The Tony Kornheiser Show

Play Episode Listen Later Mar 9, 2022 66:17


Tony opens the show by reading a few emails, and he also talks about the major news in the NFL with Aaron Rodgers staying in Green Bay and Russell Wilson going to Denver. Steve Sands of the Golf Channel calls in to preview the TPC and also about Phil Mickelson's flirtation with the proposed Saudi tour, Washington Post columnist Sally Jenkins calls in to talk about the corruption within the IOC, and Tony closes out the show by opening up the Mailbag. Songs : Post Sex Nachos “I Got This Feeling That Won't Let Go” ; Elle Celeste “Call On Me” Learn more about your ad choices. Visit podcastchoices.com/adchoices

Fore Play
Recapping Best Golf Trip In History + Rocco Mediate & David Feherty

Fore Play

Play Episode Listen Later Mar 8, 2022 123:29 Very Popular


The boys spent the last week in Monterey having the time of their life on the best golf trip ever, The Dad Bod Classic. Riggs & Lurch recap how their team won and Frankie's intense match with Colt Knost. Also, Scottie Scheffler won, it's TPC week, Tiger is being inducted into the hall of fame, and more. Then we're joined by David Feherty (53:41) to talk Tiger's hall of fame career and Rocco Mediate (01:12:37) who talks about his legendary U.S. Open duel with Tiger and life on the Champions Tour

numberFire Daily Fantasy Podcasts
The Heat Check: PGA THE PLAYERS Championship 2022

numberFire Daily Fantasy Podcasts

Play Episode Listen Later Mar 8, 2022 81:30


TPC Sawgrass will test the world's best golfers in this week's PLAYERS Championship with a massive payout on the line. Which golfers could emerge in a tough field to post big scores for PGA DFS? numberFire's Brandon Gdula and Jim Sannes preview THE PLAYERS, discussing how TPC Sawgrass typically plays, optimal roster construction for the event, and the top options in each salary tier on FanDuel.